EF Hutton analyst Jason Kolbert initiated coverage of Humacyte with a Buy rating and $25 price target. Humacyte is focused on developing engineered human tissues and virtual organs with it primary innovation the creation of human acellular vessels, the analyst tells investors in a research note. The firm says the HAVs are designed to be durable, resistant to infection, and capable of long-term storage, offering potential advantages over traditional synthetic or donor-derived grafts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Hertz Global Holdings call volume above normal and directionally bullish
- Humacyte presents long-term results of ATEV in vascular trauma
- Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program
- Small Cap Stocks: FDA Delay Created Buy-On-The-Dip Opportunity for Humacyte (HUMA)
- Humacyte reports Q2 EPS (48c) , consensus (24c)